Kazakhstan National vs EAEU Medical Device Registration: How to Choose the Right Pathway

1. Key takeaways

If your target market is Kazakhstan alone and your evidence package is already in place or nearly complete, choose national registration. This is the most frequent correct choice in the country’s dual-track system: a national registration certificate carries no expiry date, one grant locks in long-term market access, and the national procedure accepts existing clinical data generated outside the union, so studies do not need to be repeated inside the EAEU. If your target market covers two or more EAEU member states, choose union registration. Under the protocol signed on December 29, 2025, the window for filing new applications under the national rules of a member state closes on December 31, 2027; after that date, new applications can only follow the union pathway. A union certificate covers five markets at once, namely Russia, Belarus, Kazakhstan, Armenia and Kyrgyzstan, which converts a single evaluation into five authorizations. The two tracks are not mutually exclusive: the same company may hold national certificates for mature products while running union registrations for newly developed products, and the only discipline this portfolio approach demands is consistent dossier version control. The GRZAN decision standard is straightforward: decide by market scope first, weigh evidence readiness second, and anchor every national-route new application to the December 31, 2027 deadline rather than to internal convenience.

2. Legal basis

3. Expert insights

Insight one: the national route’s acceptance of foreign clinical data is a seriously undervalued advantage. Under Kazakhstan’s own national registration procedure, the applicant may rely on clinical study data already generated abroad, eliminating the need to organize expensive and time-consuming local clinical studies inside the union. For manufacturers that already hold clinical evidence from the EU or the US, this single provision determines the national pathway’s advantage in both time and cost. The saving is not limited to the study budget itself: setting up sites, obtaining ethics approvals and recruiting subjects inside the union can add many months that no amount of documentation effort can recover. When GRZAN models a filing calendar for a Kazakhstan project, the availability of existing clinical evidence is therefore treated as a first-order variable, on the same level as product classification and the choice of authorized representative.

Insight two: the union pathway’s value lies not in being stricter but in being broader. One union registration covers the markets of all five member states: Russia, Belarus, Kazakhstan, Armenia and Kyrgyzstan. If the company’s regional plan is already multi-country, the union route delivers a clearly lower cost per market; if the plan covers Kazakhstan only, the additional reference-state and recognizing-state procedures of the union route are pure overhead. A practical way to frame the comparison is unit cost per authorized market. The union dossier costs more to prepare and coordinates more authorities, but it multiplies the outcome across five countries, while the national dossier is cheaper and faster yet produces exactly one authorization.

Insight three: decisions should be anchored to December 31, 2027 but not held hostage by it. The approaching closure of the window tempts companies into a reflex of taking the national certificate first and thinking later. The GRZAN standard is this: if new products will still need to enter other union countries after 2028, the evidence package should be prepared now at union-rule depth, because a national certificate solves the problem of one certificate, not the problem of one product line. Companies that treat the window as a trigger for evidence architecture rather than as a race for paper avoid rebuilding their dossiers twice within a few years and keep both routes open at the moment it matters.

Insight four: both pathways can coexist in the same company’s product portfolio. There is no global constraint forcing an either-or choice between the two routes. The same company may run mature products through the national route to lock in Kazakhstan access, while taking newly developed products through the union route to cover several countries at once. What genuinely needs to be managed is dossier version consistency: the same product must never carry two mutually contradictory technical files across the two tracks, since regulators on either track may request cross-references at any time.

4. Practical recommendations

1. Answer one question first: will you enter other union countries such as Russia or Belarus within the next three years? If yes, take the union route; if no, take the national route.
2. For products that already hold EU or US clinical evidence, evaluate the national pathway first and convert the direct acceptance of that evidence into a quantified time and cost advantage.
3. If the union route is chosen, prepare the evidence package to union-rule depth now; do not wait until the national certificates are in hand.
4. When both pathways coexist in the portfolio, establish a unified dossier version control mechanism so that one product never carries two contradictory technical files.
5. Put December 31, 2027 into the project schedule as the hard cut-off date for national-route new applications.

5. Verification checklist

• □ The list of target countries for the next three years is defined (Kazakhstan only, or including other union member states)
• □ The acceptability of existing foreign clinical evidence has been assessed
• □ If the national route is chosen, the filing date falls before December 31, 2027
• □ If the union route is chosen, the choice of reference state and recognizing states has been evaluated
• □ A dossier version control mechanism is in place for the coexistence of both pathways in the portfolio
• □ The route decision is documented in writing with reasons attached

GRZAN provides registration support in Kazakhstan for medical device manufacturers, importers and authorized representatives, covering route selection, dossier preparation, expert review follow-up and post-grant registration maintenance. For assistance with this topic, contact info@grzanglobal.com.

Regulatory information verified as of October 29, 2026.